Drilldown: Medicines

Other values:

Search

None (10) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dalmane (1) · Doral (1) · Edronax (1) · Fetzima (1) · Halcion (1) · Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) · Lexotan (1) · Librium (1) · Ludiomil (1) · Marplan (1) · Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) (1) · Mogadon (1) · Nardil (1) · Norpramin (1) · Onfi (1) · Parnate (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Savella (1) · Serax (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Tranxene (1) · Treximet (1) · Valdoxan (1) · Versed (1) · Vivactil (1) · Xanax (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (2) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-000015CE-QINU`"' The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses'"`UNIQ--ref-000015CF-QINU`"'. (1)

None (40) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000011-QINU`"' (1) · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-000015D0-QINU`"' (1)

None (40) · 0.25 mg (1) · 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours (1) · 25 mg (1) · 5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours (1) · Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1)

None (40) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric) (1) · Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) · Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg (1)

None (40) · 10 mg/d (1) · 2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache (1) · 200 mg/d (1) · 200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra) (1) · 30 mg/24 hours (1)

None (39) · intranasal (1) · Oral (6) · subcutaneous (1)

None (39) · 10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) · 30 minutes for migraine relief (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Headache relief at 30-60 minutes (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (39) · 2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) · 4-6 hours; headache recurrence is common (1) · 4-8 hours (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · Chronic daily dosing (1) · Long (1)

None (39) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2 hours'"`UNIQ--ref-00000015-QINU`"' (1) · 2-3 hours'"`UNIQ--ref-00000012-QINU`"' (1) · Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"' (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (39) · 80-90% oral (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' (1) · ~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) · ~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"' (1) · ~50% (highly variable) (1)

None (39) · Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (39) · Rx-only (1) · Rx-only in US (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (2) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' (1)